This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 13, Issue 1 pp 411—423
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development
Figure 2. BTZ@HMSNs restricts the proliferation of lymphoma. (A) Cell viability of SNK-1 cells treated with PBS (control), HMSNs, BTZ (set from 1 to 150 nM), HMSNs+BTZ (containing 1-150 nM of BTZ) and BTZ@HMSNs (containing 1-150 nM of BTZ) by MTT assay. (B) The gene expression profile of Daudi, Jurkat, Raji, SNK-1 and NK92 cells by qRT-PCR (Left). Cell viability of indicated cells treated with BTZ or BTZ@HMSNs by MTT assay (Right). (C) Colony number of SNK-1 cells treated with PBS (control), HMSNs, BTZ, BTZ@HMSNs by colony formation assay. BTZ, bortezomib; HMSNs, hollow mesoporous silica nanospheres. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. **P < 0.01 and ***P < 0.001. Values are means ± SD.